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Background: Inhalation of a single dose of the long-acting [3e-adrenoceptor agonist 
salmeterol protects against methacholine-induced airway obstruction and other 
bronchoconstricting stimuli for at least 12 hours. Hypothetically, twice daily dosing of 
~almeterol may result in continuous protection. 
Objective: This study was designed to investigate the protective ffect of a single dose of 
salmeterol and of continuous twice daily treatment on airway responsiveness to methacholine. 
Methods: In a double-blind, parallel study, salmeterol 50 lag twice daily was compared with 
salbutamol 200 tag twice daily. Thirty children with mild asthma, who had little or no 
bronchial obstruction and were hyperresponsive to methacholine (PDeo <-- 150 txg) were 
allocated to receive ither salmeterol or salbutamoL Airway responsiveness was measured 
before study entry, 12 hours after a single dose of drug was given, and monthly during 4 
months of daily treatment. Measurements were always performed at the same time of the day, 
12 hours after the last dose of medication was administered. 
Results: No significant differences in FEV 1 were found between treatments at any time point. 
PD eo significantly increased after the first dose of salmeterol was given (geometric mean. 100 
lag). Geometric mean PDeo values were significantly better during salmeterol treatment than 
during salbutamol treatment. 52 and 25 lag, respectively (p = 0.0051. 
Conclusion: The protection provided by salmeterol during maintenance treatment was less 
than that provided after the first dose (p < O.O01L However. protection did not diminish 
during the 4-month treatment period and remained significant compared with baseline (p = 
O. 003). (J ALLERGY CLIN IMMUNOL 1996;97:938-46. ) 
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Salmeterol  x inafoate has a bronchodi lat ing ef- 
fect that lasts for at least 12 hours when adminis- 
tered as a single dose of  50 I~g in adults and 
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Abbreviations used 
DD: Doubling dose 
FVC: Forced vital capacity 
PEFR: Peak expiratory flow rate 
chi ldren with asthma, a4 Protect ion against metha- 
chol ine- induced 2,3 and histamine- induced airway 
obstruct ion lasts for 12 up to 24 hours. Single-dose 
studies also show a pro longed protect ion against 
other  bronchoconstr ict ing stimuli, such as exer- 
cise, 5 hyperventi lat ion with dry cold air. 6 and aller- 
gen. 7 Theoretical ly, twice daily dosing of  salme- 
terol can provide 24-hour protect ion against 
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various bronchoconstricting stimuli and therefore 
decrease symptoms in patients with asthma. Stud- 
ies comparing salmeterol 50 Ixg twice daily with 
salbutamol 200 Ixg four times daily during 12 weeks 
have indeed shown better symptom control in the 
group treated with salmeterol. 8~~ In patients with 
mild asthma a reduction of the acute protective 
effect of salmeterol against methacholine-induced 
bronchoconstriction from a 3.3 doubling dose 
(DD) after the first dose to a 1.0 DD after stopping 
maintenance treatment at 4 and 8 weeks was 
found. 11 The bronchodilating effect did not change 
during the study period. Another study in patients 
with mild to moderate asthma, of whom the ma- 
jority were treated with inhaled corticosteroids, did 
not show this reduction in protection against 
methacholine-induced airway obstruction. 12 The 
two studies differ in the time point at which 
methacholine challenges were performed, 1and 12 
hours after salmeterol administration, respectively; 
whereas in the study by Cheung et al. ~1 mainte- 
nance treatment was also stopped for 36 hours. A 
recent study in adult patients with symptomatic 
asthma, who were already being treated with a low 
dose of inhaled corticosteroids, howed a response 
more favorable in symptoms and peak flow values 
when salmeterol was added than when the inhaled 
corticosteroid ose was increased. ~3 This study, 
however, does not include data on airway respon- 
siveness. We investigated the protective ffect of 
salmeterol against methacholine-induced broncho- 
constriction after a single dose and during 4 
months of maintenance treatment and compared 
this with the effect of salbutamol. 
METHODS 
Subjects 
Between July 1992 and January 1993, 30 children, 
aged 7 to 16 years, with mild asthma ccording to the 
American Thoracic Society's criteria, ~4 were recruited 
from the outpatient department for Pediatric Respira- 
tory Medicine, Sophia Children's Hospital, Rotterdam. 
The patients had to be capable of performing lung 
function tests reproducibly (i.e., a coefficient of variation 
in three consecutive measurements of FEVt less than 
5%). Because airway responsiveness is partly deter- 
mined by the degree of bronchial smooth muscle con- 
striction, ~5 we selected children who had a consistent 
increase in airway responsiveness but little or no bron- 
choconstriction. They had to meet he following criteria: 
(1) a dose of methacholine that produced a 20% fall in 
FEV~ (PD2o methacholine) qual to or less than 150 Ixg 
(this being more than 2 standard eviations below the 
mean value in healthy children), ~6 (2) a baseline FEV] 
and forced vital capacity (FVC) greater than 70% of 
predicted value (reference values according to Zapletal 
et al.X7), and (3) an FEVJFVC greater than 70%. The 
inclusion criteria had to be fulfilled at a prestudy visit. 
All patients were atopic to one or more inhaled aller- 
gens, as determined by measurement of specific IgE in 
serum and/or positive skin test results. Their households 
were adapted to reduce house dust mite exposure, and 
keeping of domestic animals was discouraged. Asthma 
treatment before the study consisted of an inhaled 
132-agonist on demand only or in combination with 
maintenance treatment with disodium cromoglycate. 
Inhaled corticosteroids and maintenance treatment with 
oral corticosteroids were not allowed in the year preced- 
ing the study. Disodium cromoglycate was stopped 2 
weeks before the start of the run-in period. If during this 
period the symptoms of asthma increased significantly, 
the patient was excluded from the study. None of the 
children had acute episodes of asthma or respiratory 
tract infections for at least 1 month before entry into the 
study. 
Thirty children, 20 boys and 10 girls, were allocated 
randomly to treatment groups (15 in each group). The 
baseline Characteristics were the same for each treat- 
ment group (Table I). Nine children in each treatment 
group had had disodium cromoglycate medication dis- 
continued. The median duration of asthma was 5 and 6 
years, respectively, for the salmeterol and salbutamol 
groups. The exacerbation rate was low in both groups, 
reflected by the mean number of prednisolone courses 
per patient in the preceding year, respectively, 0.13 and 
0.20. None of the children had been hospitalized for 
treatment of asthma in the year before entering the 
study. 
Study design 
The study had a double-blind, parallel-group design 
and consisted of a 2-week run-in period, a 4-month 
treatment period, and a 2-week follow-up period. The 
study was based on an intention-to-treat principle. At 
the first visit to the lung function laboratory, before the 
start of the run-in period, children were randomly 
allocated to receive ither salmeterol 50 I~g twice daily 
or salbutamol 200 ~g twice daily. During the run-in 
period no medication was given, except for salbutamol in
case of symptoms. The first dose of the study drug was 
taken at the end of the run-in period, 12 hours before 
the second visit. Thereafter, the 4-month treatment 
period started, and children took their study medication 
two times a day with an interval of approximately 12 
hours. For relief of acute asthma symptoms, albutamol 
was allowed at a maximum dose of 200 I~g sex times daily. 
Exacerbations of asthma were treated with a standard 
short course of prednisolone (starting with 30 mg on the 
first day and tapering off to 0 in 1 week according to a 
scheme that depended on body weight). Saibutamol and 
the study medication were administered asRotadisks in 
combination with a Diskhaler (Glaxo, Greenford, U.K.). 
All children were instructed in use of this inhalation 
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TABLE I. Patient characteristics at time of entry into the study 
Age FEV 1 FVC FEV1/FVC PD2o 
Subject No.* Sex (yr) (% pred) (% pred) (%) (l~g) Medication Atopy 
Salmeterol group 
1 M 9 93 97 80 34 B HD. C, D 
2 F 13 90 112 68 6 B HD, Gr, D 
3 M 7 106 107 84 23 BC HD 
4 M 11 99 90 92 75 B HD, Gr 
5 M 15 96 115 68 17 BC HD. Gr. C, D 
6 F 12 104 107 82 4 BC HD. Gr. C, D 
7 M 6 87 94 78 48 B HD. Gr, C 
8 M 11 74 82 75 16 B Gr 
9 M 7 84 79 90 92 BC HD. Gr 
i0 M 7 102 97 89 49 BC HD, Gr, C. D 
11 F 10 94 95 85 66 BC HD, Gr. C, D 
12 M 8 95 87 92 39 B HD. C. D 
13 F 12 99 99 85 136 BC Gr 
14 M 10 97 96 85 54 BC HD, Gr. C. D 
15 M 10 76 77 83 25 BC C 
Mean 10.3 93.0 95.5 82.5 32.4+ 
SD 2.5 9.5 11.6 7.6 
Salbutamol group 
16 F 11 103 106 82 101 B HD 
17 M 7 111 121 80 28 BC HD, Gr. C 
18 M 11 103 113 76 123 B HD, Gr 
19 M 11 81 103 66 27 BC HD, Gr, C. D 
20 F 7 96 111 75 14 BC HD, Gr, C 
21 F 11 84 89 81 24 BC HD, Gr, C 
22 M 12 91 84 90 83 BC HD, D 
23 F 11 92 94 83 107 BC HD 
24 F 7 103 103 86 25 B HD, Gr. C 
25 F 7 87 81 93 20 BC HD, Gr. C, D 
26 M 12 82 86 80 27 BC HD 
27 M 12 77 82 78 26 B HD 
28 M 10 73 73 83 45 B HD 
29 M 8 96 88 91 41 B HD, C. D 
30 M 10 89 97 78 21 BC HD 
Mean 10.3 91.2 95.3 81.5 37.2-t 
SD 2.0 10.9 13.6 7.0 
B. Inhaled 132-agonist ondemand: HD. house dust; C. cat; D, dog; Gr. grass: BC. inhaled Bz-agonist and disodium cromoglycate. 
*Subject numbers do not indicate the sequence of entry into the study. 
eGeometric mean. 
device before entry into the study, and technique was 
checked at every visit. During the follow-up period after 
the study medication was stopped, salbutamol was used 
as needed. Children visited the lung function laboratory 
at the start and at the end of the run-in period, monthly 
during the treatment period, and at the end of the 
follow-up period. At each visit heart rate. blood pres- 
sure. FEV1, peak expiratory flow rate (PEFR), and 
airway responsiveness to methacholine were measured. 
All lung function measurements were performed be- 
tween 8:30 and 9:30 AM. 12 hours after the last dose of 
the study drug was given. To verify compliance with the 
last dose. patients were asked for the exact ime of drug 
inhalation. If this was not 12 hours earlier, lung function 
measurements were rescheduled. Rescue salbutamol 
was allowed up to 8 hours before the measurements 
were taken. No FEV1 measurements or methacholine 
provocation tests were performed within the first 4 
weeks after prednisolone was taken. During the run-in 
and follow-up periods and during the first 2 weeks of 
every month of treatment, a record card was completed 
daily. Separate daytime and nighttime scores from 0 to 3 
were given for the presence and severity of cough, 
wheezing, and dyspnea. PEFR was recorded in triplicate 
twice daily before inhalation of the study drug with the 
use of a mini-Wright peak flow meter (Clemente Clarke 
International Ltd.. Harlow, Essex. U.K.). The use of 
rescue salbutamol was also recorded. At the start and 
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end of the treatment period, blood samples were taken 
and analyzed for hematologic and biochemical parame- 
ters, and urine was analyzed for protein, glucose, and 
blood. 
The study was approved by the Medical Ethics Com- 
mittee of the University Hospital/Sophia Children's 
Hospital Rotterdam. Written informed consent was 
obtained from all patients and their parents. 
Lung function measurements 
FEV1 was measured according to the European Com- 
munity for Steel and Coal recommendations 18 with a 
water-sealed spirometer (Mijnhardt, Zeist, The Nether- 
lands). The largest value from an envelope curve con- 
sisting of three to five attempts was recorded. Reference 
values of Zapletal et al. 17 were used. PEFR was mea- 
sured in triplicate, and the best value was recorded with 
the use of the patient's own mini-Wright peak flow 
meter. Methacholine provocation tests were performed 
with a modification of the dosimeter method of Chai, as 
described previously. 19 Nebulized methacholine bro- 
mide in unbuffered saline solution was given in doubling 
concentrations (0.125 to 32 mg/ml). The aerosol was 
generated by a DeVilbiss 646 nebulizer (DeVilbiss Co., 
Somerset, Pa.), attached to a Rosenthal-French dosim- 
eter (Laboratory for Applied Immunology, Fairfax, Va,) 
and driven by air at 137.8 kPa (20 psi) with a timing 
adjustment of0.6 second. A total of 20 txl of aerosolized 
solution was delivered to the mouth in four consecutive 
breaths. Mouth doses were 2.5 to 640 p.g of methacho- 
line. Saline solution was inhaled before methacholine to
exclude a nonspecific response. The effect of each dose 
was determined by measuring FEV~ in triplicate 3 
minutes after each administration. The PD2o methacho- 
line was calculated from a log dose-response plot by 
linear interpolation of data points. 
Statistical analysis 
FEV1 results were expressed as percent predicted 
value according to reference values? 7All PD2o values 
were logarithmically transformed before analysis. For 
patients in whom a 20% fall in FEV~ was not reached 
after the maximum dose of 640 Ixg methacholine, PD2o 
was considered to be 640 p~g. Because this only occurred 
in two patients, both in the salmeterol group, this has 
resulted in a slight underestimation f the effect of 
salmeterol. PD2o values were analyzed as geometric 
mean, as well as changes from baseline, expressed in 
DDs. Comparisons of PD2o and of FEV 1 between and 
within treatment groups were done by using repeated- 
measures analysis of variance. 2~ Comparisons of PD2o 
and of FEV~ at and between specific time points were 
done by using the t test and the paired t test, respectively. 
The percentage ofdays with symptoms and mean morn- 
ing and evening PEFR for individual patients were 
calculated from the daily record card for each study 
period. If the number of days scored on the daily record 
card was less than 7 (of the required 14 days), the 
percentage of days with symptoms or peak flow rates 
were considered inestimable for that item in that period 
and were not included in the analysis. Comparisons of 
the percentages of days with symptoms in various study 
periods were done by using the Mann-Whitney U test. 
Comparisons of mean morning and mean evening 
PEFRs at and between specific study periods were done 
by using the t test and the paired t test, respectively. For 
all analyses, ap value of 0.05 (two-sided) was considered 
the limit of significance. 
RESULTS 
During the study, six prednisolone courses were 
given: three during salmeterol treatment (subject 
2, one course; and subject 7, two courses) and 
three during salbutamol treatment (subjects 18, 19, 
and 29). Two children (subjects 7 and 18), one in 
each treatment group, withdrew during the treat- 
ment period because of an increase in symptoms; it
was considered unethical to continue administra- 
tion of blinded medication. After withdrawal, both 
children began receiving inhaled corticosteroids. 
Measurements obtained from these subjects were 
included up to the last visit before withdrawal. 
Compliance with treatment schedules were 
checked by counting the used blister packs at each 
visit. The compliance gradually improved during 
the treatment period in both treatment groups: 
from 1.11 to 1.76 blister packs/day for the group 
treated with salmeterol and from 1.10 to 1.90 
blister packs/day for the group treated with salbu- 
tamol. 
Airway caliber 
Results of FEV], expressed in liters and percent 
predicted value, are listed in Table II. At the 
beginning of the run-in period, FEVI was similar in 
both groups. Twelve hours after the first dose of 
either of the study drugs was administered, we 
found no significant change in FEV a compared 
with baseline values. At no time, either after the 
first dose was given or during the treatment period, 
were there any significant changes in FEV1 within 
or between the two treatment groups. Two weeks 
after the discontinuation of salmeterol treatment, 
a small but significant (p = 0.005) decrease in 
FEVa occurred. However, the fall in FEV1 after 
continuous treatment was stopped did not differ 
between the salmeterol and salbutamol groups 
(p = 0.10). 
Airway responsiveness 
Baseline PD2o methacholine values were similar 
in the salmeterol and salbutamol groups (geomet- 
ric mean, 32 and 37 Ixg methacholine, respective- 
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lO dose 
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Salmeterol:- 1.7 (.3) 0.6 (.4) 1.0 (.4) 0.6 (.3) 0.8 (.4) 0.0 (.3) 
Salbutamol:- -0.5 (.2) -0.3 (.3) -0.5 (.3) -0.6 (.3) --0.5 (.4) -0.3 (,2) 
FIG. 1. PD2o methacholine (geometric mean _ SEM) at all time points. Mean PD2o changes from 
baseline in DDs (-+SEM) for salmeterol and salbutamol treatment are listed below the time 
points. 
TABLE II. Results of FEV1 expressed in liters and as percent predicted for both treatment groups 
at different time points 
Salmeterol Salbutamol 
L % pred L % pred 
Baseline 1.98 +-- 0.17 93.0 --- 2.5 2.00 _+ 0.13 91.2 +- 2.8 
Visit 2 (12 hr after 2.08 _+ 0.22 95.5 --+ 4.2 1.99 -+ 0.12 90.3 -+ 2.8 
first dose) 
Treatment period 
1 mo 2.04 __+ 0.19 94.3 -+ 3.1 2.03 -+ 0.14 90.3 -+ 3.4 
2 mo 1.97 - 0.17 92.8 + 2.9 2.06 -+ 0.12 92.0 +-- 2.4 
3 mo 2.07 _+ 0.19 93.2 _+ 3.0 1.98 + 0.12 88.0 _+ 2.1 
4 mo 2.02 -+ 0.19 90.5 ___ 4.1 1.96 + 0.15 87.3 - 3.1 
Follow-up 1.95 -+ 0.18 85.7 _+ 3.1 1.97 _+ 0.14 86.2 + 2.1 
Values  are expressed as means  +_ SEM.  
ly). There was a strong correlation between PD2o 
values at the different time points and baseline 
values of PD2o within treatment groups. Therefore 
to reduce the variation caused by interindividual 
differences in baseline PD2o , not only geometric 
mean PD20 values were analyzed but also changes 
in PD2o from baseline. The results of these analy- 
ses were similar. Fig. 1 shows both geometric mean 
PD20 values and PD2o changes in DDs. Table I I I  
shows individual data at each time point. 
At the end of the run-in period, 12 hours after 
the first 50 txg dose of salmeterol was given, PD2o 
methacholine increased by 1,66 DD compared 
with baseline. After administration of 200 ~g of 
salbutamol, PD2o fell with a 0.54 DD (p < 0,001 
salmeterol vs salbutamol). Geometric mean PD2o 
values at this time point were 100 and 26 p.g 
methacholine, respectively, for salmeterol and sap 
butamol (p = 0.001). The individual results are 
plotted in Fig. 2. 
During the treatment period no significant 
changes in geometric mean PD2o were found 
within both groups from 1 to 4 months. The 
geometric mean PD20 during the treatment period 
was 52 ~g methacholine for the salmeterol group, 
compared with 25 ~g methacholine for the salbu- 
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TABLE III. Individual data for PD=o (in micrograms of methacholine) at different time points 
Treatment period (mo) 
Single Follow 
Subject No. Baseline dose 1 2 3 4 up 
Salmeterol group 
1 34 89 127 73 24 21 11 
2 6 14 * * 13 12 11 
3 23 13 20 26 41 35 13 
4 75 >640 428 504 103 221 199 
5 17 410 169 179 56 216 51 
6 4 32 18 28 21 11 8 
7 48 55 * 201 * * * 
8 16 20 19 19 * 21 32 
9 92 338 142 118 50 101 105 
10 49 208 59 51 63 68 48 
11 66 167 35 31 28 136 20 
12 39 108 10 101 65 13 50 
13 136 >640 101 117 >640 >640 69 
14 54 99 51 50 54 44 20 
15 25 97 23 46 44 * * 
Geometric mean 32 100 52 71 50 54 32 
Salbutamol group 
16 101 36 77 31 29 52 90 
17 28 13 35 11 34 60 58 
18 123 28 30 31 23 * * 
19 27 28 123 62 45 * 43 
20 14 9 10 9 10 10 16 
21 24 29 7 55 33 19 21 
22 83 80 174 183 140 37 75 
23 107 52 56 31 72 26 33 
24 25 37 29 17 16 13 13 
25 20 24 7 11 13 10 12 
26 27 28 20 12 16 24 16 
27 26 20 20 15 21 51 22 
28 45 32 47 67 7 11 24 
29 41 9 * 11 8 9 20 
30 21 25 30 36 50 104 44 
Geometric mean 37 26 31 26 25 24 28 
*No measurements. 
tamol group (p = 0.005). The geometric mean 
PD2o was less during maintenance treatment with 
salmeterol than after the first dose was given (p < 
0.001) but still significant compared with baseline 
(p = 0.003). Two weeks after maintenance treat- 
ment was stopped, geometric mean PD2o values 
were not significantly different between groups. 
For both treatment groups these values did not 
differ significantly from the values at the time of 
entry into the study. 
Dai ly record cards 
Symptom scores were generally low. Mean per- 
centages of days with at least one symptom were 
46% and 40%, respectively, for the salbutamol and 
salmeterol groups during the run-in period. For 
the group treated with salmeterol, these percent- 
ages were 32%, 25%, 22%, and 23%, respectively 
during the four consecutive treatment periods. 
These percentages did not significantly differ from 
the percentages for the group treated with salbu- 
tamol, which were 35%, 34%, 30%, and 25%, 
respectively (all p > 0.59). No significant differ- 
ences were found when the various symptoms-- 
cough, wheezing, and shortness of breath--were 
analyzed separately. This also applied to the sep- 
arate morning and evening symptom scores. Morn- 
ing and evening PEFRs did not differ significantly 
within or between groups, although both tended to 
increase during salmeterol treatment. 
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FIG. 2. Individual results of PD2o methachol ine for both treatment groups at baseline period 
(visit 1) and 12 hours after the first dose of the study drug was given (visit 2). 
Adverse events 
During salmeterol treatment 17 adverse vents 
were reported in 10 patients; during salbutamol 
treatment 36 adverse vents were reported in 12 
patients. Most adverse vents were upper respira- 
tory tract symptoms. Headache occurred slightly 
more often during salbutamol treatment (eight 
periods of headache in four patients) than during 
salmeterol treatment (one headache). There were 
no significant changes in systolic and diastolic 
blood pressure or heart rate in any group during 
treatment. 
DISCUSSION 
The results of this study show that twice daily 
treatment with salmeterol in children with mild 
asthma results in continuous, stable protection 
against methacholine-induced bronchoconstric- 
tion. This protection, however, is less than the 
protection provided after a first single dose. After 
maintenance treatment was stopped for 2 weeks, 
no residual protection remained, indicating that 
there was no sustained reduction of airway respon- 
siveness. 
Salbutamol instead of placebo was used in the 
control group; otherwise, because of its bronchodi- 
latory effect salmeterol could be recognized as the 
effective treatment. Twice daily treatment with 
salbutamol resulted in a slight but not significant 
decrease (p = 0.06) in PD2o during the 4-month 
period compared with baseline measurements; this 
was probably the result of withdrawal of disodium 
cromoglycate in more than half of the children 
before they entered the study. Some authors have 
suggested an increase in airway responsiveness and 
a deterioration of asthma as a result of regular 
[32-agonist treatment. 2 ,22 It is unlikely, however, 
that regular use of salbutamol is the explanation 
for the decrease of PD20 in the salbutamol group in 
our study, because the decrease in PD20 was al- 
ready present at the end of the run-in period in 
which children used salbutamol "as needed." 
We selected children with mild asthma, who 
were hyperresponsive but had little or no broncho- 
constriction, to avoid interference with airway cal- 
iber and PD20. We chose to measure airway re- 
sponsiveness 12 hours after the last dose of the 
study drug was administered, which is the normal 
dose interval during maintenance treatment with 
salmeterol and therefore clinically relevant. Fur- 
thermore, a longer interval might introduce a 
rebound increase in airway responsiveness, a  has 
been shown for up to 59 hours after stopping 
regular treatment with the short-acting [32-agonists 
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terbutaline 23 and salbutamol. 24 Until now, a re- 
bound increase in PD20 after stopping regular 
treatment with salmeterol has not been demon- 
strated.11, 2, 25, 26 
In our study the protective ffect of salmeterol 
was probably caused by the prolonged effect of the 
drug on airway smooth muscle. This is functional 
antagonism, a well-known phenomenon associated 
with other [32-adrenoceptor agonists. 27 In vitro 
experiments show evidence of an interaction of 
132-agonists and methacholine atthe level of intra- 
cellular signal transduction through phosphoinosi- 
tide metabolism. 28 
After the first dose of salmeterol was given, we 
found an improvement in PDzo of 1.7 DD, which is 
comparable with the results of previous tudies. 2,3, 29 
During the treatment period from 1 to 4 months, this 
protection was constant but reduced to 0.7 DD. 
Two studies in adult patients with asthma inves- 
tigated the immediate protective ffect of salmet- 
erol and the effect during regular twice daily 
treatment.l~, 12 Booth et al. 12 examined 26 patients 
with mild to moderate asthma in a parallel-group, 
placebo controlled study. The majority of their 
patients were also receiving inhaled corticosteroid 
treatment. As in our study, the interval between 
salmeterol administration and measurement of
airway responsiveness to methacholine was 12 
hours. They found a small but significant protec- 
tion during 8 weeks of salmeterol treatment, which 
did not differ from the single dose effect. 12 A 
reduction in protection during regular twice daily 
treatment with salmeterol was found by Cheung et 
al. ~ They reported a reduction in protection from 
3.3 DD after the single dose of salmeterol was 
given to 1.0 DD after 4 and 8 weeks of treatment. 
Airway responsiveness was measured 1 hour after 
salmeterol administration, and maintenance treat- 
ment was stopped for 36 hours. Although unlikely 
from the data at the end of their study, a possible 
rebound increase in airway responsiveness could 
not be excluded. As in our study, Cheung et al. l~ 
selected subjects with mild asthma who were not 
treated with inhaled corticosteroids. The reduction 
in protection occurred within 4 weeks after the 
start of maintenance treatment and remained at 
the same level after 8 weeks of treatment. The 
explanation for this tolerance remains unclear but 
may be the result of receptor downregulation. 
Tachyphylaxis to nonpulmonary effects (e.g., 
tremor, increased QTc interval, and elevated blood 
glucose levels) has been found after 2 weeks of 
treatment with salmeterol in healthy subjects. 3~ 
The use of inhaled corticosteroids may protect 
against he development of tachyphylaxis to pul- 
monary effects of 132-agonists and may explain the 
different results obtained by Booth et al. 12 Rever- 
sal of tachyphylaxis bysystemic orticosteroids has 
been shown in vitro and in vivo. 31 
In our study significant, stable protection re- 
mained throughout the 4 months of treatment 
with salmeterol. So, if any downregulation f the 
132-receptors occurs, this seems incomplete. Be- 
cause we selected children with little or no 
bronchoconstriction, the effect could not be ex- 
plained by an improvement in airway caliber. 14 
This is supported by the fact that no significant 
changes occurred in FEV 1 and that no correla- 
tion was found between the changes in PD20 and 
in F!EV 1. Although the protection after 4 weeks 
of treatment was less than that after the first 
dose was given, our data do not indicate an 
ongoing increase in airway responsiveness. A 
significant degree of protection remained uring 
treatment, and this may be of clinical relevance, 
because a decrease in airway responsiveness will 
improve the tolerance to other exogenous stim- 
uli. A direct correlation has been found between 
the degree of airway responsiveness to a nonspe- 
cific stimulus and the amount of allergen that 
can be tolerated. 32, 33 In our study the changes in 
airway responsiveness were not reflected by 
changes in symptom scores. However, this may 
be the result of selecting patients with mild 
asthma who already have very low symptom 
scores before the start of the study. 
We conclude that the protective ffect of salme- 
terol against methacholine-induced airway ob- 
struction during 4 months of treatment is lower 
than the protection offered by a single dose. How- 
ever, twice daily administration f salmeterol pro- 
vides significant, stable protection compared with 
baseline and salbutamol treatment. 
According to international consensus reports, 
asthma therapy should be directed against air- 
way inflammation, and inhaled corticosteroids 
are now the mainstay of asthma treatment. 34 It is 
unlikely from the data now available that salme- 
terol in itself influences chronic airway wall 
inflammation. 35 Addition of salmeterol to in- 
haled corticosteroid treatment may have benefi- 
cial effects on symptom scores and airway re- 
sponsiveness. 13 Studies are now being performed 
in children with asthma to evaluate the effect of 
addition of salmeterol to treatment with a con- 
ventional dose of an inhaled corticosteroid, as 
compared with increasing the dose of an inhaled 
coi'ticosteroid. 
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